A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)

Trial Profile

A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Bortezomib; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 02 Dec 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 18 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top